OBJECTIVES:  Despite the availability of a wide number of treatments for relapsed/refractory (r/r) chronic lymphocytic leukemia (CLL) and r/r mantle cell lymphoma (MCL), no standard of care has emerged. There are no studies evaluating preferences for treatment outcomes for r/r CLL and r/r MCL. This study was designed to elicit preferences for r/r MCL and r/r CLL treatment outcomes among patients, the general public and physicians experienced in treating CLL/MCL in Germany. METHODS: Interviews (90 minutes) in German of 6 CLL/6 MCL hematologists, 6 r/r CLL and 5 r/r MCL patients were conducted (total 23 interviews). Participants were asked to state their most important treatment outcomes. Transcripts were translated to English and analyzed by counting the number of times each outcome was mentioned. We present here results of patient and physician preferences. RESULTS: r/r CLL patients mention overall survival (OS; 5 counts), mode of treatment administration (4), quality of life (QOL) aspects (4) and progression free survival (PFS) disease control (4). A tolerable side effect (SE) profile/controlling disease symptoms was mentioned by 3 patients. Other treatment outcomes were infections, nausea (2 each), fatigue, weight loss, pain, fever, polyneuropathy and long treatment intervals (1 each). CLL physicians mentioned OS (4), QOL (4) and PFS (4). r/r MCL patients mentioned efficacy benefits such as cure (4) and OS (2), PFS (1); various QOL aspects (5) and a tolerable SE profile/controlling disease (3). Other treatment outcomes were long-term organ damage (2), hair loss, nausea and night sweat (1 each). MCL physicians mentioned OS (6), QOL (5) and a tolerable SE profile (4). CONCLUSIONS: Extending life, disease control, maintaining QOL and avoiding SE are important r/r MCL/CLL treatment outcomes to German patients and physicians.